New COPD drug aims to cut flare-ups in patients with high eosinophils

NCT ID NCT06897748

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This study tests an investigational drug called tozorakimab in adults with symptomatic COPD who have had at least two moderate or one severe flare-up in the past year and have high levels of eosinophils (a type of white blood cell). Participants receive either tozorakimab or a placebo every two weeks for 12 weeks, followed by a 10-week follow-up. The main goal is to see if the drug improves lung function and reduces the number of COPD flare-ups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Aramil, 624002, Russia
Research Site

Izhevsk, 426061, Russia
Research Site

Moscow, 105554, Russia
Research Site

Moscow, 117546, Russia
Research Site

Moscow, 119048, Russia
Research Site

Moscow, 125284, Russia
Research Site

Omsk, 644099, Russia
Research Site

Penza, 440067, Russia
Research Site

Perm, 614000, Russia
Research Site

Saint Petersburg, 193231, Russia
Research Site

Saratov, 410054, Russia
Research Site

Ulyanovsk, 432009, Russia

Conditions

Explore the condition pages connected to this study.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)